Pilihan Pengobatan Sistemik pada Psoriasis
DOI:
https://doi.org/10.55175/cdk.v49i3.213Keywords:
Antibodi monoklonal, psoriasisAbstract
Psoriasis adalah salah salah satu penyakit autoimun dengan prevalensi tinggi. Gejala dan tanda psoriasis sangat bervariasi mulai dari ruam kulit kecil sampai luas, nyeri sendi, bahkan komorbiditas sistemik. Pengobatan psoriasis perlu disesuaikan, serta mempertimbangkan efikasi, keamanan, dan kenyamanan pasien. Apabila pengobatan topikal tidak berhasil, dapat dipertimbangkan pengobatan sistemik. Artikel ini akan membahas kelebihan dan keterbatasan pilihan-pilihan pengobatan sistemik untuk psoriasis.
Psoriasis is an autoimmune disease with a high prevalence. Symptoms and signs of psoriasis vary widely from small to extensive skin rashes, joint pain, and even systemic comorbidities. Treatment need to be tailored to each patient’s needs, also to efficacy, safety, and patient’s comfort. Systemic treatment could be considered if topical treatment is unsuccessful. This article will discuss the advantages and limitations of systemic treatment options in psoriasis.
Downloads
References
Golbari NM, Porter ML, Kimball AB. Current guidelines for psoriasis treatment: A work in progress. Cutis 2018;101(3S):10–2.
Parisi R, Symmons DPM, Griffiths CEM, Ashcroft DM, Identification and management of psoriasis and associated comorbidiTy (IMPACT) project team. Global epidemiology of psoriasis: A systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377–85.
Psoriasis: Practice essentials, background, pathophysiology [Internet]. 2019 Oct 21 [cited 2019 Oct 22]. Available from: https://emedicine.medscape.com/article/1943419-overview#a3
Sarac G, Koca TT, Baglan T. A brief summary of clinical types of psoriasis. North Clin Istanb. 2016;3(1):79–82.
Menter MA, Armstrong AW, Gordon KB, Wu JJ. Common and not-so-common comorbidities of psoriasis. Semin Cutan Med Surg. 2018;37(2S):48–51.
Oji V, Luger TA. The skin in psoriasis: Assessment and challenges. Clin Exp Rheumatol. 2015;33(5 Suppl 93):14-9.
Mrowietz U, Kragballe K, Reich K, Spuls P, Griffiths CEM, Nast A, et al. Definition of treatment goals for moderate to severe psoriasis: A European consensus. Arch Dermatol Res. 2011;303(1):1–10.
Overview | Psoriasis: Assessment and management | Guidance | NICE [Internet]. [cited 2019 Oct 25]. Available from: https://www.nice.org.uk/guidance/cg153
Elmets CA, Lim HW, Stoff B, Connor C, Cordoro KM, Lebwohl M, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy. J Am Acad Dermatol. 2019 Sep;81(3):775–804.
Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019 Apr;80(4):1029–72.
Sbidian E, Chaimani A, Garcia-Doval I, Do G, Hua C, Mazaud C, et al. Systemic pharmacological treatments for chronic plaque psoriasis: A network meta-analysis. Cochrane Database Syst Rev. 2017;12(12):CD011535.
Sawyer LM, Cornic L, Levin LÅ, Gibbons C, Møller AH, Jemec GB. Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response. J Eur Acad Dermatol Venereol JEADV. 2019;33(2):355–66.
British Association of Dermatologists - Forms/Downloads [Internet]. [cited 2019 Oct 22]. Available from: http://www.bad.org.uk/healthcare-professionals/formsdownloads.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
